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We investigated the impact of rabbit antithymocyte globulins (ATG) on patient outcomes after allogeneic stem
cell transplantation (allo-SCT) for progressive myelodysplastic syndrome (MDS). Of the 242 consecutive pa-
tients who underwent allo-SCT for progressive MDS between October 1999 and December 2009, 93 received
ATG (ATG group) at the median dose of 5 mg/kg, whereas 149 patients did not (no-ATG group). Donors were
sibling (n ¼ 153) or HLA-matched unrelated (n ¼ 89). Patients received blood (n ¼ 90) or marrow (n ¼ 152)
grafts after either myeloablative (n ¼ 109) or reduced-intensity (n ¼ 133) conditioning. Three-year overall and
event-free survival, nonrelapse mortality, relapse, and chronic graft-versus-host disease (GVHD) development
were not signiﬁcantly different between the 2 groups. In contrast, acute grade II to IV GVHD occurred more
often in the no-ATG group (55% of the patients) than in the ATG group (27%, P < .0001). Similar results were
observed with acute grade III to IV GVHD (28% and 14% in the no-ATG group and ATG group, respectively;
P ¼ .009). In multivariate analysis, after adjustment with propensity score, the absence of ATG was theedgments on page 653.
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R. Duléry et al. / Biol Blood Marrow Transplant 20 (2014) 646e654 647strongest parameter associated with an increased risk of acute grade II to IV GVHD (hazard ratio, 2.13; 95%
conﬁdence interval, 1.35 to 3.37; P ¼ .001]. ATG had no impact on overall and event-free survival or cumulative
incidence of the relapse. In conclusion, the addition of ATG to allo-SCT conditioning did not increase the
incidence of relapse of patients with progressive MDS. The incidence of acute GVHD was decreased without
compromising outcomes.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION Participating centers veriﬁed the data recorded for each patient in theFigure 1. Flow chart for patient selection strategy. *Patients whose ﬁles were
missing data for at least 1 of the following were excluded: initial French-
American-British (FAB)/World Health Organization (WHO) category, Interna-
tional Prognostic Scoring System (IPSS) score and cytogenetic features at
diagnosis, disease status before transplantation, and use of antithymocyte
globulin (ATG) as part of the conditioning.Allogeneic hematopoietic stem cell transplantation (allo-
SCT) remains the only potentially curative therapeutic
approach in patients with myelodysplastic syndrome (MDS).
Despite the beneﬁcial effects of allo-SCT, these patients are at a
substantial risk of relapse after transplantation [1-4]. Disease
status is amajor factor that inﬂuences patientoutcomewith an
increased risk of relapse, especially in patients with progres-
sive disease [5]. Indeed, disease status at transplantation can
be broken down into 2 categories according to the Interna-
tional Working Group 2006 response criteria: (1) responding,
for patients with complete, marrow, and partial remission or
stable disease with hematological improvement; and (2) pro-
gressive disease including refractory, relapsing, progressive
and stable disease without hematological improvement [6].
Although signiﬁcant improvements in HLA matching
techniques have been accomplished [7], allo-SCT is still
limited by the immunological recognition and destruction of
host tissues, termed graft-versus-host disease (GVHD). Both in
its acute and chronic forms, GVHD continues to be the major
source of morbidity and mortality after allo-SCT [8]. Severe
acute GVHD has a poor prognosis, with 5-year overall sur-
vival of 25% for grade III and 5% for grade IV disease [9].
One of the strategies developed to reduce the risk of
GVHD is ex vivo T cell depletion of the graft. Although this
has been proven to be very effective to prevent GVHD, this is
also associated with a signiﬁcant increase in graft failure and
risk of relapse [10,11]. An alternative strategy is to provide
in vivo T cell depletion in blood and lymphoid tissues using
antithymocyte globulin (ATG), a set of polyclonal antibodies
directed against a wide range of immune cell epitopes [12].
However, the use of ATG, incorporated within the condi-
tioning regimen before allo-SCT, is still controversial, espe-
cially for patients with progressive disease. Indeed, the risk
of GVHD seems to be reduced in various proportions with
ATG [13-20] but a signiﬁcant increase of disease relapse has
also been observed [21,22]. In addition, the impact of ATG on
the incidence of relapse is still unknown in the subgroup of
patients with progressive disease.
In an attempt to assess the impact on outcomes of rabbit
ATG incorporated within the conditioning regimen, we
report a multicenter retrospective study of 242 consecutive
patients who underwent an allo-SCT for progressive MDS.
PATIENTS AND METHODS
The study was approved by the French Society of Bone Marrow Trans-
plantation and Cell Therapy board and conducted according to the decla-
ration of Helsinki.
Patient Selection
Transplantationmodalities were made as homogenous as possible using
the following inclusion criteria: patients older than 18 years with MDS who
were referred for ﬁrst allo-SCT. The source of stem cells was the bone
marrow or blood from either a sibling or an unrelated donor that was HLA-A,
-B, -Cw, -DR, and -DQ identical at allelic level. Patients with chronic myelo-
monocytic leukemia and those who received allo-SCT from an HLA-
mismatched donor or cord blood or a T celledepleted graft were excluded.
Thymoglobuline (Genzyme Corporation, Cambridge, MA) was the only ATG
administered to the patients, as this is the only brand approved in France for
use in allo-SCT.French Bone Marrow Transplantation Registry and provided additional in-
formation. Quality of the data and HLA matching were controlled by using a
computerized search for discrepancy errors. Consequently, 461 consecutive
patients who underwent allo-SCT between October 1999 and December
2009 in 24 French and Belgian centers were identiﬁed. Thirty-six patients
were excluded because their ﬁles lacked data. Because the objective of this
study was to investigate the impact of ATG on patients with progressive
MDS, we excluded the 183 patients who responded to pretransplantation
treatment according to InternationalWorking Group 2006 criteria [6]. Of the
242 remaining patients, 93 received ATG during conditioning (ATG group)
and 149 did not (no-ATG group, n ¼ 149) (Figure 1).
Patient and Donor Characteristics and Transplantation Modalities
Disease morphology was classiﬁed according to the French-American-
British and World Health Organization (WHO) classiﬁcations [23,24] and
the International Prognostic Scoring System (IPSS) score was calculated at
diagnosis according to Greenberg et al. [25]. Progression to more advanced
disease between diagnosis and transplantation, responses, and disease sta-
tus at transplantation were evaluated according to standard criteria [6,26].
Patient and donor initial characteristics at diagnosis and transplantation
are shown in Table 1. The use of ATG was center-based in line with national
guidelines [27]. The ATG and no-ATG groups were unbalanced in terms of
recipient age, stem cell source, number of CD34þ cells in the graft, condi-
tioning, use of total body irradiation, and GVHD prophylaxis. However, there
was no difference between the 2 groups regarding the other patient char-
acteristics, including French-American-British/WHO classiﬁcation, IPSS
score, and cytogenetic risk category at diagnosis. In the ATG group, the drug
was delivered at a dose of < 5 mg/kg (n ¼ 6), 5 mg/kg (n ¼ 53, 57%), 7.5 mg/
kg (n¼ 11), or 10 mg/kg (n ¼ 10). ATG was infused over 1 day (n¼ 6), 2 days
(n ¼ 45, 48%), 3 days (n ¼ 19), 4 days (n ¼ 7), or 5 (n ¼ 4) days.
STATISTICAL ANALYSES
The analysis was performed on the reference date of April
1, 2011. Overall survival (OS) was deﬁned as the time elapsed
from allo-SCT to death, regardless of the cause of death.
Event-free survival (EFS) was deﬁned as survival with no
evidence of relapse. Relapse was deﬁned as the presence of
more than 5% marrow blasts and/or reappearance of major
myelodysplastic features associated with evidence of
Table 1
Patient and Donors Characteristics and Transplantation Modalities
Characteristic Total (n ¼ 242) ATG (n ¼ 93) No-ATG (n ¼ 149) P Value*
At diagnosis
Gender .27
Male 151 (62) 62 (67) 89 (60)
Female 91 (38) 31 (33) 60 (40)
FAB/WHO .85
RA/RARS/RCMD 90 (37) 34 (37) 56 (38)
RAEB-1 82 (34) 30 (32) 52 (35)
RAEB-2 60 (25) 24 (26) 36 (24)
RAEB-t/AML 10 (4) 5 (5) 5 (3)
IPSS .22
Low/int-1 139 (57) 58 (62) 81 (54)
Int-2/high 103 (43) 35 (38) 68 (46)
Cytogenetics .74
Favorable 115 (47) 47 (50) 68 (46)
Intermediate 65 (27) 23 (25) 42 (28)
High risk 62 (26) 23 (25) 39 (26)
At transplantation
Recipient age, median (range), yr 52 (20-70) 56 (21-68) 50 (20-70) <.0001
Gender mismatchy 53 (22) 21 (23) 32 (22) .83
WBC 109/L, median (range) 2.4 (.1-78) 2.3 (.1-33) 2.6 (.1-78) .36
Hemoglobin gr/dL, median (range) 9.1 (5.2-15.9) 8.8 (5.2-13.8) 9.3 (5.6-15.9) .24
Platelet 109/L, median (range) 55 (1-696) 52 (3-696) 56 (1-600) .57
Marrow blasts, median (range) 7 (0-64) 7 (0-50) 7 (0-64) .43
Disease status .61
Nonresponders 242 (100) 93 (100) 149 (100)
Pretransplantation progression 67 (28) 25 (26) 43 (29)
Donor type .29
Sibling 153 (63) 55 (59) 98 (66)
HLA-matched unrelated 89 (37) 38 (41) 51 (34)
Stem cell source .0001
Marrow 90 (37) 17 (18) 73 (49)
PBSC 152 (63) 76 (82) 76 (51)
CD34þ 106/kg, median (range) 4.8 (.4-26.8) 5.65 (.8-26.8) 4.2 (.41-19.3) .003
Conditioning .0001
MAC 109 (45) 9 (10) 100 (67)
RIC 133 (55) 84 (90) 49 (33)
TBI .0001
No 146 (60) 82 (88) 64 (43)
Yes 96 (40) 11 (12) 85 (57)
GVHD prophylaxis .0001
Cs-A and MTX 119 (50) 23 (25) 96 (64)
Cs-A and other drugs 120 (50) 67 (75) 53 (36)
FAB indicates French-American-British classiﬁcation; WHO, World Health Organization; RA, refractory anemia; RARS, refractory anemia with ring sideroblasts;
RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts; RAEB-t, RAEB in transformation; AML, acute myeloid
leukemia; IPSS, International Prognostic Scoring System; int, intermediate; WBC, white blood cells; PBSC, peripheral blood stem cells; MAC, myeloablative
conditioning; RIC, reduced-intensity conditioning; TBI, total body irradiation; GVHD, graft-versus-host disease; Cs-A, Cysclosporine A; MTX, short course of
methotrexate.
Data presented are n (%) unless otherwise indicated.
* Comparison of the ATG and “no-ATG” groups using Mann-Whitney U test, or Chi-squared test, as appropriate.
y Gender mismatch is deﬁned as male recipient who received graft from female donor.
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Nonrelapse mortality (NRM) was deﬁned as death resulting
from the transplantation procedure without evidence of
relapse. Estimated 3-year event rates were reported because
the number of events beyond 3 years was insufﬁcient
for accurate estimates. Estimated 100-day event rates
were assessed for acute GVHD and neutrophil and platelet
engraftment.
For continuous variables, medians and ranges were de-
termined. The assumption of normality was assessed using
the Shapiro-Wilk test. Categorical variables were described
by frequencies and percentages. The 2 groups of patients
(ATG and no-ATG) were compared using the chi-square or
the Fisher exact tests for categorical data. For continuous
variables, ANOVA or Kruskal-Wallis tests were applied
according to the distribution of the studied variable. All
censored criteria were calculated from the time of trans-
plantation. Distributions over time were estimated by the
Kaplan-Meier product limit method. The log-rank test wasused to test the prognostic value of patient characteristics at
transplantation for the occurrence of the event. Variables
having a signiﬁcance level of P < .10 from the univariate
analyses were introduced in a multivariable Cox regression,
with backward selection at level P < .10. ATG was always
included in the selection, whatever its signiﬁcance level in
univariate analysis. Adjusted hazard ratios and 95% conﬁ-
dence intervals (CI) were computed and P  .05 was
considered statistically signiﬁcant.
The occurrences of engraftment, relapse, NRM, acute
GVHD, and chronic GVHD were studied by using competing
risk methodology. For the events relapse and GVHD, death
without experiencing the event was considered as a com-
peting event. For NRM, the competing event was relapse. The
cumulative incidence of each event was estimated using the
Kalbﬂeish and Prentice method [28]. The individual prog-
nostic value for each variable was assessed by the Gray’s test
(comparison of cumulative incidence curves: bivariate ana-
lyses). ATG and variables having a signiﬁcance level of P< .10
R. Duléry et al. / Biol Blood Marrow Transplant 20 (2014) 646e654 649in the bivariate analyses were introduced in a multivariate
Fine and Gray model [29]. Adjusted hazard ratio and 95%
conﬁdence intervals were computed.
Because our study was not randomized, we used a pro-
pensity score to adjust P values for patients who received
ATG and those who did not [30]. Thus, patients were sub-
sequently analyzed, and P values were also adjusted using
the propensity score method according to whether they had
received ATG or not. The propensity score model included
signiﬁcant variables in bivariate analyses and those that
might have inﬂuenced the outcome of allo-SCT. These
included recipient’s age,WHO category, cytogenetic features,
and IPSS at diagnosis; pretransplantation progression to a
more advanced disease; percentage of marrow blasts at
transplantation; pretransplantation treatment; cytomegalo-
virus (CMV) recipient and donor serostatus; stem cell source;
conditioning; and GVHD prophylaxis.
Statistical analyses were performed by using SAS software
(SAS Institute, Cary, NC). For the Fine and Gray model, the R
package “cmprsk” was used (R Foundation for Statistical
Computing, Vienna, Austria; http://www.r-project.org/).RESULTS
Patient Outcome
On the date of analysis of April 1, 2011, the median follow-
up was 38.7 months (range, 15.2 to 65.6). All but 14 patients
experienced neutrophil engraftment after a median time of
17 days (range, 0 to 70) (Table 2). One hundred and seven
patients (44%) developed grade II to IV acute GVHD,
including 55 patients (23%) with grade III to IV. Of the 200
evaluable patients who survived more than 100 days, 112
(56%) developed chronic GVHD including 78 (38%) with
extensive grade. For the whole group of patients, the median
3-year OS, EFS, relapse, and NRM were 45%, 39%, 31%, and
30%, respectively.Bivariate Analysis
As expected, among all the patient characteristics ana-
lyzed, IPSS score and cytogenetics signiﬁcantly inﬂuenced
OS, EFS, and relapse (Table 3). Best supportive care before
transplantation, stable disease, and marrow blasts <5% at
transplantation were signiﬁcantly associated with improved
OS and EFS and a lower rate of relapse. Patients younger than
51.7 years and those who received a graft from a donorTable 2
Transplantation-Related Events
Event Total
(n ¼ 242)
ATG
(n ¼ 93)
No-ATG
(n ¼ 149)
P Value*
Patients who engrafted, n (%) 228 (94) 87 (94) 141 (95) .47
Time to ANC>500/mL, median, d 17 17 18 .95
Time to platelet >20  109/L, d 16 13 18 .002
Acute GVHD, n (%)
0-I grades 135 (66) 68 (73) 67 (45)
II-IV grades 107 (44) 25 (27) 82 (55) <.0001
III-IV grades 55 (23) 13 (14) 42 (28) .012
Chronic GVHD, n (%)
(200 evaluable patients)
None 88 (44) 40 (51) 48 (39)
All forms (versus none) 112 (56) 38 (49) 74 (61) .065
Extensive (versus none) 78 (38) 22 (28) 56 (46) .057
Relapse rate at 3 years, n (%) 76 (31) 31 (33) 45 (30) .36
Nonrelapse mortality at 3 years,
n (%)
72 (30) 23 (20) 49 (33) .11
ANC indicates absolute neutrophil count; GVHD, graft-versus-host disease.
* Comparison of the ATG and no-ATG groups.younger than 45.5 years relapsed less often (P ¼ .005 and
P ¼ .004, respectively) and had better EFS (P ¼ .031 and
P ¼ .037, respectively) than the others. The cumulative inci-
dence of relapse was also increased with reduced-intensity
conditioning (RIC) regimen (P ¼ .003) and graft from a
CMV-seropositive donor (P ¼ .004). Only 2 factors adversely
inﬂuenced NRM: male patients (P ¼ .03) and myeloablative
conditioning (MAC) regimen (P ¼ .029).
Outcome According to ATG Use in Conditioning
As shown in Table 3 and Figure 2, patients in the ATG
group developed acute grade II to IV GVHD less often (27%)
than those in the no-ATG group (55%; P < .0001). Moreover,
severe acute GVHD (grade III to IV) occurred in 14% of the
patients in the ATG group versus 28% in the no-ATG group
(P ¼ .009). However, there was no signiﬁcant difference be-
tween the 2 groups in terms of 3-year OS (50% versus 42%;
P ¼ .25), 3-year EFS (42% versus 36%; P ¼ .56), cumulative
incidence of relapse (34% versus 31%; P ¼ .46) and NRM (24%
versus 36%; P ¼ .10). These results were similar in the sub-
group of patients who progressed to a more advanced dis-
ease before transplantation (Table 4). Of note, the use of ATG
tended to reduce the risk of chronic GVHD (P ¼ .065 for all
forms and P ¼ .057 for extended forms) (Table 2).
Multivariate Analyses
As shown in Table 5, the most important factor associated
with the development of grade II to IV acute GVHD was the
absenceofATG in conditioning (hazard ratio [HR], 2.13; 95%CI,
1.26 to 3.61; P ¼ .0049). Conversely, ATG had no impact on 3-
year OS (HR, 1.25; 95% CI, .85 to 1.85; P ¼ .26), EFS (HR, 1.28;
95% CI, .81 to 2.04; P ¼ .30), relapse (HR, 1.36; 95% CI, .71 to
2.59; P¼ .35) andNRM(HR,1.19; 95%CI, .68 to 2.13; P¼ .54). All
these results were conﬁrmed by propensity score analyses.
The detrimental role of a high-risk cytogenetics was
conﬁrmed for 3-year OS (HR, 2.05; 95% CI, 1.23 to 3.42;
P ¼ .006), EFS (HR, 2.12; 95% CI, 1.22 to 3.53; P ¼ .004), and
cumulative incidence of relapse (HR, 2.88; 95% CI, 1.55 to
5.37; P ¼ .0008). The 3-year OS was also inﬂuenced by pre-
transplantation treatment; cytoreductive drugs were asso-
ciated with less satisfactory OS (HR, 1.67; 95% CI, 1.11 to 2.59;
P ¼ .013). Finally, the other factors most closely associated
with a higher risk of relapse were graft from a CMV-
seropositive donor (HR, 2.32; 95% CI, 1.37 to 3.93; P ¼ .002)
and RIC regimen (HR, 2.49; 95% CI, 1.14 to 5.44; P ¼ .022).
DISCUSSION
Findings from this study suggest that the addition of
rabbit ATG to the conditioning regimen before allo-SCT can
lead to a decreased incidence of acute GVHD without wors-
ening post-transplantation outcomes in patients with MDS
who are at high risk of relapse. These results were conﬁrmed
after adjustment with a propensity score that included the
main patient and disease characteristics and transplantation
modalities.
To the best of our knowledge, this is the largest study
reporting on the role of ATG incorporated within the con-
ditioning regimen of allo-SCT for patients with progressive
MDS. Several studies have previously reported on ATG in
pretransplantation setting [13-17,21]. However, the inter-
pretation of the results of these studies is difﬁcult because
none of them restricted the inclusion criteria to a homoge-
neous disease setting and disease status. In addition, some of
these studies included patients who received allo-SCT from
Table 3
Bivariate Analysis by Key Subsets: Three-Year Overall and Event-free Survival, Relapse, Nonrelapse Mortality, and Acute Grade 2 to 4 GVHD Rates
Factor No. of Patients Overall
Survival
EFS Relapse NRM Grade II-IV
Acute GVHD
% P* % P* % Py % Py % P*
Gender
Male 151 44 .69 37 .57 32 .89 32 .03 42 .17
Female 91 46 41 32 31 49
Patient age, yr
<51.7 122 50 .25 47 .031 23 .005 33 .79 35 .0008
51.7 120 40 30 41 31 54
IPSS .045
Low/int-1 139 52 .02 44 26 .03 33 .77 42 .39
Int-2/high 103 36 31 39 31 48
Cytogenetics
Favorable 115 52 .02 45 .015 26 .0003 32 .27 42 .74
Intermediate 65 46 42 24 39 46
High risk 62 30 23 52 24 48
Gender mismatchz .87
No 187 45 .93 39 32 .79 33 .53 44 .91
Yes 53 43 38 34 29 43
Pretransplantation progressionx
No 173 49 .02 43 .006 29 .05 30 .43 45 .84
Yes 67 36 28 40 35 43
Pretransplantation treatment
BSC 160 52 .0007 43 .003 29 .024 30 .25 46 .64
Cytoreductive 67 30 27 43 34 40
Marrow blasts at transplantation .022
5% 87 50 .08 48 19 .0007 35 .53 41 .42
>5% 130 36 31 41 30 48
Donor age, y
<45.5 120 51 .15 46 .037 24 .004 32 .75 47 .31
45.5 117 39 31 41 30 42
Recipient CMV serostatus
Negative 112 48 .33 40 .34 33 .79 29 .34 50 .09
Positive 130 42 40 31 35 40
Donor CMV serostatus
Negative 119 49 .20 43 .13 24 .004 36 .30 50 .10
Positive 122 40 33 40 29 40
Donor type
Sibling 153 44 .91 37 .62 36 .09 30 .36 45 .73
HLA-matched unrelated 89 47 42 25 35 44
Stem cell source
Marrow 90 45 .84 38 .93 27 .14 37 .16 55 .009
PBSC 152 45 38 35 29 38
Conditioning
MAC 109 47 .97 41 .68 22 .003 39 .029 56 .0002
RIC 133 43 36 40 26 35
Antithymocyte globulin
No 149 42 .25 36 .56 31 .46 36 .10 55 <.0001
Yes 93 50 42 34 24 27
Total body irradiation
No 146 47 .21 41 .22 31 .60 29 .32 44 .85
Yes 96 41 34 34 36 46
GVHD prophylaxis
Cs-A and MTX 119 47 .35 43 .093 27 .09 33 .83 51 .04
Cs-A and other drugs 120 43 35 36 31 38
EFS indicates event-free survival; NRM, nonrelapsemortality; GVHD, graft-versus-host disease; IPSS, International Prognostic Scoring System; int, intermediate;
BSC, best supportive care; CMV, cytomegalovirus; BSC, peripheral blood stem cells; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; Cs-A,
Cysclosporine-A; MTX, short course of methotrexate.
* Log-Rank.
y Gray (cumulative incidence).
z Gender mismatch is deﬁned as male recipient who received graft from female donor.
x Encompasses patients who progressed to a more advanced disease before transplantation.
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founding factors [13,14,21].
Bacigalupo et al. [15] showed in the early 2000s that pre-
transplantation rabbit ATG (Thymoglobuline) administration
decreased the risk of acute and chronic GVHD. However, these
study reported only small series (75 patients included in 2
different trials), which precluded authors from drawing ﬁrm
conclusions. In 2009, Finke et al. [14] analyzed the addition of
a different brand of rabbit ATG (ATG Fresenius, FreseniusBiotech, Waltham, MA) to standard GVHD prophylaxis in 201
patients enrolled in a prospective, randomized, multicenter
trial. Patients with various hematologic malignancies (acute
and chronic leukemia, MDS, and osteomyeloﬁbrosis) received
MAC before allo-SCT from matched unrelated donors. Donors
and recipients were only required to be HLA-A, -B, -DRB1 and
-DQB1 identical (8 out of 8 alleles), and HLA-C mismatch was
present in 35 cases. The addition of ATG Fresenius resulted in a
decreased incidence of acute and chronic GVHD without
Figure 2. Kaplan-Meier estimates of (A) 3-year overall survival, (B) 3-year event-free survival, (C) cumulative incidence of 3-year relapse, and (D) grade II to IV acute
graft-versus-host disease (GVHD) in 242 patients, according to the administration of antithymocyte globulin (ATG) in the conditioning. HR indicates hazard ratio;
CI, conﬁdence interval; ns, not signiﬁcant.
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Data from Mohty et al. [13] conﬁrmed these results with ATG
Thymoglobuline in a retrospective report on 120 patients with
acute leukemia and MDS undergoing allo-SCT from matched
unrelated donors after MAC.
The impact of rabbit ATG was also analyzed with RIC in a
retrospective multicenter study on 1676 adults undergoing
transplantation for hematologic malignancies. Soiffer et al.
[21] reported a higher risk of relapse with ATG compared to
Tcellereplete regimens (51% and 38%, respectively; P< .001).
Although these data are supported by a large series, their
interpretation may be confounded by the lack of homoge-
neity of the underlying diseases (acute and chronic leukemia,
MDS, osteomyeloﬁbrosis, and lymphoma) and the condi-
tioning regimens. Conversely, in a recent phase 2 prospective
study [16], patients with hematologic malignancies under-
went allo-SCT from HLA-identical sibling and were ran-
domized between 2 different strategies of conditioning:
ﬂudarabine was associated with either busulfan and ATGTable 4
Bivariate Analysis by Key Subsets in the Sub-Group of Patients Who Progressed to a
Event-Free Survival, Relapse, and Nonrelapse Mortality Rates
No. of Patients Overall Survival
% P*
Antithymocyte globulin
No 43 33 .42
Yes 25 46
EFS indicates event-free survival; NRM, nonrelapse mortality.
* Log-rank.
y Gray (cumulative incidence).(n ¼ 69) or total body irradiation alone (n ¼ 70). After 5-year
follow-up, the busulfan-ATG regimen was associated with
greater disease control. However, because of higher NRM
rate, this did not translate into better OS. Recently, deMasson
et al. [22] assessed the outcomes of 37 cases of advanced-
stage primary cutaneous T cell lymphomas treated with
allo-SCT in a multicenter retrospective analysis. In multi-
variate analysis, the use of rabbit ATG was the only factor
associated with an increased incidence of relapse (HR, 4.8;
95% CI, 1.8 to 12.9; P ¼ .002) and a reduced progression-free
survival (HR, 2.9; 95% CI, 1.3 to 6.2; P ¼ .04). This demon-
strates that ATG may have a different impact on relapse
depending on the disease treated with allo-SCT.
We, therefore, chose to restrict our study to only 1 disease
and focused on progressive patients, hypothesizing that ATG
before transplantation could have a signiﬁcant impact on
outcome in this setting. Because the outcome of allo-SCT
depends on the degree of donor-recipient HLA matching
[31], we only included patients who received allo-SCT fromMore Advanced Disease before Transplantation: Three-Year Overall Survival,
EFS Relapse NRM
% P* % Py % Py
26 .68 37 .65 37 .22
33 46 21
Table 5
Multivariate Analyses
Characteristics 3-Year Overall Survival 3-Year Event-Free
Survival
3-Year Relapse Grade II-IV Acute GVHD
HR 95% CI P* HR 95% CI P* HR 95% CI P* HR 95% CI P*
Recipient age, yr
<57.6 -y 1 1 1
57.6 1.23 .78-1.91 .37 1.38 .71-2.68 .34 .68 .43-1.09 .11
Donor age, yr
<44.9 - 1 1 -
44.9 1.10 .73-1.64 .65 1.09 .64-1.88 .74
Cytogenetics -
Low 1 1 1
Intermediate 1.63 1.04-2.57 .033 1.52 .97-2.39 .066 1.02 .52-1.98 .96
High risk 2.05 1.23-3.42 .006 2.12 1.22-3.53 .004 2.88 1.55-5.37 .0008
IPSS at diagnosis -
Low/int-1 1 1 1
Int-2/high 1.33 .83-2.13 .24 1.26 .80-1.99 .31 1.01 .56-1.83 .97
Pretransplantation progressionz
No 1 1 1 -
Yes 1.33 .85-2.09 .21 1.33 .85-2.07 .21 1.45 .80-2.62 .21
Pretransplantation treatment
BSC 1 1 -
Cytoreductive 1.67 1.11-2.59 .013 1.34 .88-2.04 .18
Marrow blasts at transplantation
<5% 1 1 1
5% .90 .55-1.46 .66 1.01 .63-1.62 .97 1.73 .88-3.41 .11
CMV recipient serostatus
Negative - - - 1
Positive .84 .57-1.25 .39
CMV donor serostatus
Negative - - 1 1
Positive 2.32 1.37-3.93 .002 .86 .58-1.28 .45
Donor type
Sibling - - - -
HLA-matched unrelated
Stem cell source
Marrow - - - 1
PBSC .86 .54-1.38 .54
Conditioning
MAC - - - 1.14-5.44 .022 1
RIC .86 .47-1.55 .61
ATGx
ATG group 1 1 1 1
No-ATG group 1.25 .85-1.85 .26 1.28 .81-2.04 .30 1.36 .71-2.59 .35 2.13 1.26-3.61 .0049
GVHD prophylaxis -
Cs-A and MTX 1 1 1
Cs-A and other drugs 1.15 .72-1.85 .57 1.67 .88-3.16 .11 1.2 .71-2.02 .49
HR indicates hazard ratio; CI, conﬁdence interval; GVHD, graft-versus-host disease; IPSS, international prognostic scoring system; int, intermediate; BSC, best
supportive care; CMV, cytomegalovirus; PBSC, peripheral blood stem cells; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; ATG,
antithymocyte globulin; Cs-A, Cysclosporine A; MTX, short course of methotrexate.
Antithymocyte globulin and variables having a signiﬁcance level of P < .10 in the bivariate analyses were introduced in a multivariate model.
* P  0.05 was considered statistically signiﬁcant.
y Variables having a signiﬁcance level of P > .10 in the bivariate analyses.
z Encompasses patients who progressed to a more advanced disease before transplantation.
x Propensity score analyses: the absence of ATG was signiﬁcantly associated with acute grade II to IV GVHD (HR, 2.13; 95% CI, 1.35 to 3.37; P ¼ .0012).
However, there was no impact of ATG on 3-year OS (P ¼ .11), EFS (P ¼ .10), and relapse (P ¼ .30).
Bold indicates signiﬁcant P values.
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Donor-recipient HLA-matching was veriﬁed in the database
of the French National Donor Registry as previously de-
scribed [32]. In addition, data were cross checked meticu-
lously using different methods of veriﬁcation (matching of
several sources of data, on-site veriﬁcation, and computer-
ized search for discrepancy errors).
Given the retrospective nature of our study, we used a
propensity score adjustment in multivariate analyses to
accurately identify the impact of ATG on patient outcome, by
balancing the covariates in the 2 groups and reducing bias
when treatment assignment was not random [30].
In line with previous reports [13-21], we found that the
absence of ATG had a detrimental impact on acute GVHD
development. However, one may question the reasons whysuch a beneﬁcial effect of ATG in reducing acute GVHD does
not have an effect on survival. Indeed, measuring the out-
come of allo-SCT therapy is difﬁcult because the net outcome
is affected by several complex variables that all might have a
role in determining the ﬁnal outcome. However, better
GVHD prevention, even if it does not signiﬁcantly improve
survival, may still be a desirable approach, especially given
the overall burden of GVHD for patients. Of note, patients in
the ATG group were older and received more often an allo-
SCT after a RIC regimen than patients in the no-ATG group.
Although the recipient’s age is known to adversely inﬂuence
survival [5], RIC is known to increase the risk of relapse [33].
On the other hand, this study did not observe a signiﬁcant
impact of ATG on chronic GVHD development. Although the
difference did not reach statistical signiﬁcance, there was a
R. Duléry et al. / Biol Blood Marrow Transplant 20 (2014) 646e654 653clear trend towards less chronic GVHD in the ATG group
(P ¼ .065). Also, one should bear in mind that peripheral
blood stem cells (PBSC) were more often used in the ATG
group (82%) than in the no-ATG group (51%) (P ¼ .0001), and
PBSC use is known to be associated with an increased inci-
dence of chronic GVHD [34,35]. Therefore, the addition of
rabbit ATG as part of the conditioning regimen might have
played a role in the reduction of the expected incidence of
chronic GVHD in the ATG group.
With respect to the ATG dose impact, the majority of
patients received ATG at the total dose of 5 mg/kg. Thus, this
study did not have sufﬁcient statistical power to assess the
impact of ATG dose on patient outcome. In addition, based on
our experience and different other reports, it is likely that the
use of low to moderate doses (5 to 7 mg/kg) of ATG before
allo-SCT can decrease the risk of GVHD without increasing
the risk of relapse [36,37].
In conclusion, this study demonstrates that the addition
of ATG to conditioning regimens results in a decreased
incidence of acute GVHD without increasing the risk of
relapse or compromising survival of patients undergoing
allo-SCT for progressive MDS. Although prospective studies
are still needed to assess the optimal ATG dose and admin-
istration schedule and determine whether ATG affects im-
mune reconstitution, such a protective effect of ATG against
acute GVHD is of beneﬁt to patients undergoing allo-SCT.
With the ever-growing use of PBSC, ATG should be incor-
porated within the conditioning regimen of patients with
MDS, even if the disease is progressive.
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